This is the abstract and conclusion from a brand new paper - not yet published in J Clin Endocrinol Metab. from the Bianco lab. Pls look at it and draw your own conclusions.
COMPARATIVE EFFECTIVENESS OF LEVOTHYROXINE, DESICCATED THYROID EXTRACT, AND LEVOTHYROXINE+LIOTHYRONINE IN HYPOTHYROIDISM
Mohamed K. M. Shakir 1,2 , Daniel I. Brooks 1 , Elizabeth A. McAninch 3 , Tatiana De Lourdes Fonseca 3 , Vinh Q. Mai 1,2 , Antonio C. Bianco 4 , Thanh D. Hoang 1,2
1 Walter Reed National Military Medical Center, Bethesda MD 2 Uniformed Services University of the Health Sciences, Bethesda MD 3 Divsion of Endocrinology and Metabolism, Rush University Medical Center, Chicago IL 4 Section of Adult and Pediatric Endocrinology, University of Chicago, Chicago IL
Clinical trial number: NCT02317926.
Department of Endocrinology, Walter Reed National Military Medical Center, 8901 Wisconsin Ave. Bethesda, MD 20889-5600.
Email: tdhdthanh@gmail.com
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.
Downloaded from academic.oup.com/jcem/advan... by guest on 01 July 2021 2
Abstract
Introduction: Studies comparing LT4 therapy with LT4+LT3 or desiccated thyroid extract (DTE) did not detect consistent superiority of either treatment. Here we investigated these therapies, focusing on the whole group of LT4-treated hypothyroid patients, while also exploring the most symptomatic patients.
Methodology: Prospective, randomized, double-blind, crossover study of 75 hypothyroid patients randomly allocated to one of three treatment arms, LT4, LT4+LT3 and DTE, for 22 weeks. The primary outcomes were post-treatment scores on the 36-point thyroid symptom questionnaire (TSQ-36), 12-point quality of life general health questionnaire (GHQ-12), the Wechsler memory scale-Version IV (VMS-IV), and the Beck Depression Inventory (BDI). Secondary endpoints included treatment preference, biochemical and metabolic parameters, etiology of hypothyroidism, and Thr92Ala-DIO2 gene polymorphism. Analyses were performed with a linear mixed model using subject as a random factor and group as a fixed effect.
Results: Serum TSH remained within reference range across all treatment arms. There were no differences for primary and secondary outcomes, except for a minor increase in heart rate caused by DTE. Treatment preference was not different and there were no interferences of the etiology of hypothyroidism or Thr92Ala-DIO2 gene polymorphism in the outcomes. Subgroup analyses of the 1/3 most symptomatic patients on LT4 revealed strong preference for treatment containing T3, which improved performance on TSQ-36, GHQ-12, BDI and visual memory index (VMS-IV component).
Conclusions: As a group, outcomes were similar among hypothyroid patients taking DTE vs. LT4+T3 vs. LT4. However, those patients that were most symptomatic on LT4 preferred and responded positively to therapy with LT4+LT3 or DTE.